Overall survival · people with advanced gastric cancer
Combination probably leads to lower overall survival compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall survival · people diagnosed with chemotherapy‐induced anemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · patients with small‐volume primary oropharyngeal carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Survival ‐ overall · Women (70 years plus) with operable primary breast cancer
Surgery showed no clear difference in survival ‐ overall compared with primary endocrine therapy (low certainty).
1 finding from 1 review
Intervention not reported
Overall survival · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy
The intervention may leads to lower overall survival (low certainty).
1 finding from 1 review
Death Number of deaths over 36 months · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes overall survival (OS), measured by the number of deaths over time, compared with no neoadjuvant treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Overall survival (Duration of · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in overall survival (Duration of (high certainty).
1 finding from 1 review
Intervention not reported
Overall survival ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival: 2‐year survival rate · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in overall survival: 2‐year survival rate (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall survival: 3‐year survival rate · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in overall survival: 3‐year survival rate (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall survival: 5‐year survival rate · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in overall survival: 5‐year survival rate (moderate certainty).
1 finding from 1 review
Overall survival: mortality at 5 years · breast‐conserving radiotherapy for breast cancer
Boost showed no clear difference in overall survival: mortality at 5 years compared with no boost (moderate certainty).
1 finding from 1 review
Overall Survival ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma
Bortezomib probably leads to lower overall Survival ‐ Bortezomib versus no bortezomib (same background… compared with no bortezomib (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall survival: 1‐year survival rate  · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in overall survival: 1‐year survival rate  (low certainty).
1 finding from 1 review
Overall survival (OS) · recurrent platinum‐resistant EOC
Summary of findings 2: PLD alone showed no clear difference in overall survival (OS) compared with other conventional chemotherapy (moderate certainty).
1 finding from 1 review
Overall survival · EGFR M+ patients with NSCLC
Afatinib showed no clear difference in overall survival compared with chemotherapy (high certainty).
1 finding from 1 review
Overall survival · hormone‐sensitive prostate cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · People with advanced non‐small cell lung cancer
Gefitinib showed no clear difference in overall survival (OS) compared with chemotherapy (moderate certainty).
2 findings from 1 review
Overall survival · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy
EGFR tyrosine kinase inhibitor (TKI) showed no clear difference in overall survival compared with observation alone (low certainty).
1 finding from 1 review
Overall survival† · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.42 [0.37, 0.48]
418 participants
High